Author

Eva Verheij

PREDICTION OF MORTALITY CAUSED BY OTHER CAUSES THAN ESOPHAGEAL ADENOCARCINOMA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA USING THE CHARLSON COMORBIDITY INDEX
PREDICTION OF MORTALITY CAUSED BY OTHER CAUSES THAN ESOPHAGEAL ADENOCARCINOMA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA USING THE CHARLSON COMORBIDITY INDEX

Eva Verheij  et al.

THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES
THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES

THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES
THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES

Eva Verheij  et al.

HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS

ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them
Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Eva Verheij  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES

Eva Verheij  et al.

HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS

Eva Verheij  et al.

Barrett Oesophagus - pathophysiology, diagnosis, surveillance and treatment
Barrett Oesophagus - pathophysiology, diagnosis, surveillance and treatment

Eva Verheij  et al.

FIRST IN-HUMAN STUDY ON THE SAFETY, TOLERABILITY AND EFFICACY OF THE AQUAMEDICAL FOCAL RF-VAPOR ABLATION (RFVA) SYSTEM, FOR THE ERADICATION OF BARRETT'S ESOPHAGUS (BE): THE STEAM-BE DOSIMETRY STUDY
FIRST IN-HUMAN STUDY ON THE SAFETY, TOLERABILITY AND EFFICACY OF THE AQUAMEDICAL FOCAL RF-VAPOR ABLATION (RFVA) SYSTEM, FOR THE ERADICATION OF BARRETT'S ESOPHAGUS (BE): THE STEAM-BE DOSIMETRY STUDY

Eva Verheij  et al.

RISK OF RESIDUAL CANCER AFTER ENDOSCOPIC RESECTION OF EARLY BARRETT’S NEOPLASIA WITH CONFIRMED VERTICAL R1 MARGIN: A NATIONWIDE COHORT IN THE NETHERLANDS
RISK OF RESIDUAL CANCER AFTER ENDOSCOPIC RESECTION OF EARLY BARRETT’S NEOPLASIA WITH CONFIRMED VERTICAL R1 MARGIN: A NATIONWIDE COHORT IN THE NETHERLANDS

Eva Verheij  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK MUCOSAL ADENOCARCINOMA AND LOW- AND HIGH-RISK SUBMUCOSAL ADENOCARCINOMA ARISING IN BARRETT'S ESOPHAGUS, RESULTS OF 120 PATIENTS FROM THE DUTCH BARRETT EXPERT CENTER COHORT
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK MUCOSAL ADENOCARCINOMA AND LOW- AND HIGH-RISK SUBMUCOSAL ADENOCARCINOMA ARISING IN BARRETT'S ESOPHAGUS, RESULTS OF 120 PATIENTS FROM THE DUTCH BARRETT EXPERT CENTER COHORT

Eva Verheij  et al.

Item 1 - 12 / 12
1